IP Library › Granted Patent US 10,206,957
Granted Patent B2
US 10,206,957 · App. 16/014,971 · Granted Feb 19, 2019

Use of gram negative species to treat atopic dermatitis

Inventors: Ian Antheni Myles (Bethesda, MD); Sandip K. Datta (Bethesda, MD)
Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
A61K35/74A61K9/0014A61K9/06A61P17/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,957
App. No.
16/014,971
Granted
Feb 19, 2019
Kind
B2
Abstract

Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

Claims (14)

1. A method for treatment of atopic dermatitis, comprising:

topically administering a composition comprising at least one strain of Roseomonas mucosa to a subject in need thereof, wherein the at least one strain of Roseomonas mucosa is present in an amount sufficient for treatment of atopic dermatitis in the subject, and wherein the at least one strain of Roseomonas mucosa is isolated from a donor that does not have atopic dermatitis.

2. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is viable.

3. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is purified.

4. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is present in an amount sufficient for a reduction in Staphylococcus aureus in the subject.

5. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is present in an amount of 10 4 to 10 12 colony forming units.

6. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is topically administered by spraying.

7. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is topically administered to the subject at least two times per a week.

8. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is topically administered to the subject every other day over a week.

9. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa is topically administered to the subject daily over a week.

10. The method of claim 1 , wherein the subject is an adult.

11. The method of claim 1 , wherein the subject is a child.

12. The method of claim 1 , wherein the subject is an infant.

13. The method of claim 1 , wherein the at least one strain of Roseomonas mucosa comprises 1, 2, 3, 4, or 5 strains of Roseomonas mucosa.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2018
From: MYLES, IAN ANTHENI; DATTA, SANDIP K.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 046697/0013 →
Continuity (4)
Division 15939066 · Mar 28, 2018
Continuation PCTUS2017028133 · Apr 18, 2017
Provisional Application 62324762 · Apr 19, 2016
Related Publication 20180296612A1 · Oct 18, 2018